1. McCance-Katz EF, The National Survey on Drug Use and Health. : 2019: SAMHSA; 2020 [Available from: https://www.samhsa.gov/data/sites/default/files/reports/rpt29392/Assistant-Secretary-nsduh2019_presentation/Assistant-Secretary-nsduh2019_presentation.pdf.
2. Administration SAaMHS. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health 2020 [Available from: https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf.
3. Center for Substance Abuse T. SAMHSA/CSAT Treatment Improvement Protocols. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004.
4. Rinaldo SG, Rinaldo DW. Availability Without Accessibility? State Medicaid Coverage and Authorization Requirements for Opioid Dependence Medications: American Society of Addiction Medicine; 2013 [Available from: https://nosorh.org/wp-content/uploads/2017/05/Access-to-MAT-by-state.pdf.
5. WHO. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, Switzerland: World Health Organization; 2009.